Acute-on-Chronic Liver Failure Pipeline Insight, 2025: Biopharma Players Target Inflammation, Regeneration, and Multiorgan Support | DelveInsight

DelveInsight's "Acute-on-Chronic Liver Failure - Pipeline Insight, 2025" offers a deep dive into the evolving therapeutic landscape of ACLF, a complex and life-threatening syndrome characterized by acute hepatic decompensation in the backdrop of chronic liver disease, often accompanied by systemic inflammation and multiorgan failure. The condition carries a high short-term mortality rate, and treatment options remain severely limited, typically restricted to supportive care and liver transplantation. This has led to a surge in R&D activity aimed at identifying effective, disease-modifying therapies.

As of 2025, the ACLF pipeline includes more than 4 active companies investigating novel therapies that focus on immunomodulation, hepatic regeneration, and multi-organ support. The pipeline is exploring a wide array of mechanisms, such as inhibition of pro-inflammatory cytokines like TNF-α and IL-6, the use of stem-cell-based regenerative therapies, and extracorporeal liver support devices. Agents such as DIALIVE, developed by Yaqrit Discovery, have shown promise in clinical trials by improving systemic detoxification and modulating immune responses. G-CSF-based therapies are being evaluated for their potential to boost hepatic regeneration and enhance immune function, while mesenchymal stem cell therapies like HepaStem aim to suppress inflammation and repair liver tissue. Moreover, inhibitors targeting immune receptors like TREM1 and chemokine pathways such as CCR2/CCR5 are being developed to reduce immune cell infiltration and hepatic damage.

Growing regulatory attention, increased clinical recognition, and collaborative efforts, such as the European Association for the Study of the Liver's Chronic Liver Failure Consortium (EASL-CLIF), are fueling innovation in this space. With better diagnostic stratification tools and an enriched understanding of ACLF pathophysiology, the development of targeted, patient-specific treatments is accelerating. The 2025 pipeline signals a potential paradigm shift from passive management to proactive intervention, with therapies that could significantly delay or even reduce the need for liver transplantation, ultimately improving patient survival and quality of life.

Interested in learning more about the current treatment landscape and the key drivers shaping the acute-on-chronic liver failure pipeline? Click here: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Acute On Chronic Liver Failure Pipeline Report
• DelveInsight's acute-on-chronic liver failure pipeline analysis depicts a strong space with 4+ active players working to develop 6+ pipeline drugs for acute-on-chronic liver failure treatment.
• The leading acute-on-chronic liver failure companies include Cellaion SA, Beijing Continent Pharmaceutical Co., Ltd., Grifols Therapeutics LLC, and others are evaluating their lead assets to improve the acute-on-chronic liver failure treatment landscape.
• Key acute-on-chronic liver failure pipeline therapies in various stages of development include HepaStem, F573, PE-A 5%, and others.
• In April 2025, the FDA granted IND approval for eGenesis in collaboration with OrganOx to launch a Phase I trial testing a genetically engineered pig liver (EGEN‐5784) coupled to OrganOx's extracorporeal liver perfusion system. This trial, enrolling up to 20 ICU patients with Grade 2-3 ACLF and ineligible for transplant, aims to assess safety, performance, and potential liver support in patients with few options.
• In Feb 2025, A competitive landscape report reveals that ~71,713 diagnosed ACLF cases occurred in 2024, projected to rise to ≈73,804 by 2028. Over the past decade, 71 trials have launched, yet no therapies have reached Phase III or pre‐registration stages, highlighting the profound unmet need in ACLF treatment.

Request a sample and discover the recent breakthroughs happening in the acute on chronic liver failure pipeline landscape at https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute-on-chronic Liver Failure Overview
Acute-on-Chronic Liver Failure is a complex and life-threatening condition characterized by the sudden deterioration of liver function in individuals with pre-existing chronic liver disease, most often cirrhosis. This acute decompensation is typically triggered by factors such as infections, alcohol binge, gastrointestinal bleeding, or drug-induced liver injury. ACLF is distinguished by the presence of systemic inflammation and the rapid development of one or more organ failures, including the liver, kidneys, brain, or lungs.

The prognosis for ACLF is poor without prompt medical intervention, with high short-term mortality rates. Management focuses on treating the underlying trigger, providing supportive care for failing organs, and evaluating the need for liver transplantation. Early diagnosis, intensive care monitoring, and emerging therapies aimed at modulating inflammation and supporting liver regeneration are critical to improving patient outcomes. Ongoing research is working to better understand the pathophysiology and identify effective treatments for this devastating condition.

Find out more about acute on chronic liver failure medication at https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute On Chronic Liver Failure Treatment Analysis: Drug Profile
HepaStem: Promethera Biosciences
HepaStem is an advanced investigational therapy that targets the cells involved in the liver's inflammatory response and activates pathways essential for hepatic regeneration. By restoring liver function, HepaStem also supports the recovery of other organs affected by liver failure. The therapy is currently in Phase II clinical trials for the treatment of Acute-on-Chronic Liver Failure (ACLF).

F573: Beijing Continent Pharmaceutical Co., Ltd.
F573 is a novel dipeptide small-molecule drug with strong inhibitory activity against caspases-enzymes that play a key role in cell death and inflammation. It has shown encouraging results in preclinical models of liver failure, brain ischemia, and myocardial infarction, along with an excellent safety profile in toxicology studies in rats and dogs. F573 is currently undergoing Phase II clinical trials for the treatment of Acute-on-Chronic Liver Failure (ACLF).

Learn more about the novel and emerging acute-on-chronic liver failure pipeline therapies at https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Acute On Chronic Liver Failure Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Acute On Chronic Liver Failure Pipeline Report
• Coverage: Global
• Key Acute On Chronic Liver Failure Companies: Cellaion SA, Beijing Continent Pharmaceutical Co., Ltd., Grifols Therapeutics LLC, and others.
• Key Acute On Chronic Liver Failure Pipeline Therapies: HepaStem, F573, PE-A 5%, and others.

To dive deep into rich insights for drugs used for acute-on-chronic liver failure treatment, visit: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Acute On Chronic Liver Failure Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acute On Chronic Liver Failure Pipeline Therapeutics
6. Acute On Chronic Liver Failure Pipeline: Late-Stage Products (Phase III)
7. Acute On Chronic Liver Failure Pipeline: Mid-Stage Products (Phase II)
8. Acute On Chronic Liver Failure Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.